We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Bill Nailon
0044 1315371000
w.nailon@ed.ac.uk
Duncan McLaren
0044 1316518706
Duncan.McLaren@ed.ac.uk
Prostate Cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Nearly half of all cancer patients receive radiotherapy as part of their treatment and although it is effective at destroying cancerous lesions deep within the body, this comes at the cost of damaging healthy, or normal, tissues. With 50% of cancer patients surviving for 10 years or more, these patients can be left with life-changing side effects from their radiotherapy. It is clear that more must be done to limit damage to normal healthy tissue without compromising annihilation of the tumour and curing patients. The key to this is personalising an individual's radiotherapy treatment, in other words rather than assuming that all tumours respond similarly to radiotherapy, the treatment is optimised for an individual. To date, approaches to do this have been restricted to small numbers of carefully selected patients, are inordinately expensive, and not suitable for rolling out into everyday practice across the NHS. There is however another way, namely using Artificial Intelligence (AI) combined with an individual's healthcare record. By linking together large numbers of healthcare records at a national level, combined with the power of AI, the PROSECCA project will transform radiotherapy and cancer care.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
"Nailon WH, Noble DJ, Harrison E, Yang Z, Elliot S, MacNair A, Beckett G, Hallam A, Sheikh A, Mills N, Halliday R, Morrison D, Chalmers A, Cameron D, Gourley C, Hall P, Lilley C, Carruthers LJ, Trainer M, Burns D, Dee F, Andiappa S, Lonsdale A, Couper M, Farnan K, McLellan J, Miller A, Ogg J, Moses J, Colligan S, MacDonald G, McPhail N, Niblock P, MacLeod N, Davies ME, Laurenson DI, Hopgood JR, Boyle D, Paterson C, Grose D, Phillips I, Harrow S, Berger T, Shelley LEA, Sanders I, Henderson S, Duffton A, Mitchell J, Rutherford A, McLaren DB. Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare data. BMJ Open. 2026 Feb 2;16(2):e104408. doi: 10.1136/bmjopen-2025-104408."; "41628931"
You can take part if:
You may not be able to take part if:
This is in the inclusion criteria above
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Bill Nailon
0044 1315371000
w.nailon@ed.ac.uk
Duncan McLaren
0044 1316518706
Duncan.McLaren@ed.ac.uk
The study is sponsored by University of Edinburgh and is in collaboration with NHS Greater Glasgow and Clyde; NHS Grampian; NHS Highland; NHS Tayside; University of Glasgow; University of Lyon; NHS Lothian; NHS Research Scotland; Public Health Scotland; Prostate Cancer UK; Movember Foundation.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
